Exploratory analysis of prognostic factors and hematologic dynamics in unresectable ESCC treated with concurrent versus interval immune checkpoint inhibitors combined with (chemo)radiotherapy: a multicenter real-world study.

Consequently, while our results suggest a positive trend, the survival benefits of ICI maintenance must be interpreted with caution and ultimately require confirmation in prospective randomized controlled trials.

also in 11,005 other papers

Patients in the concurrent group had better ECOG performance status, although the difference did not reach statistical significance.

also in 111,027 other papers